INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 48m ago
HOUSE PTR8m ago
SEC 13F8m ago
ROBINHOOD CHAIN8m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Sloan Sheldon sold SYRE

Chief Medical Officer · Spyre Therapeutics, Inc. · Common Stock

Side
SELL
Value
$30K
Shares
400
Price
$75.37
Executed
May 1, 2026
Disclosed
May 1, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
May 1 executedMay 1, 2026 disclosed

SYRE · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
22/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+13 / 25

    $30K reported value · 100.0% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SYRE

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    2
    AW
    Albers Jeffrey W.Director
    SYRESpyre Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$52K
    5,000 sh
    		Aug 7, 2026Aug 10, 2026
    traded Aug 7, 2026
    		+3dSEC FORM 4

    Evidence

    3
    AW
    Albers Jeffrey W.Director
    SYRESpyre Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    5,000 sh
    		Aug 7, 2026Aug 10, 2026
    traded Aug 7, 2026
    		+3dSEC FORM 4

    Evidence

    26
    AW
    Albers Jeffrey W.Director
    SYRESpyre Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.05M
    10.0K sh
    		Aug 7, 2026Aug 10, 2026
    traded Aug 7, 2026
    		+3dSEC FORM 4

    Evidence

    19
    AW
    Albers Jeffrey W.Director
    SYRESpyre Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$835K
    8,000 sh
    		Aug 7, 2026Aug 10, 2026
    traded Aug 7, 2026
    		+3dSEC FORM 4

    Evidence

    23
    AW
    Albers Jeffrey W.Director
    SYRESpyre Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$522K
    5,000 sh
    		Aug 7, 2026Aug 10, 2026
    traded Aug 7, 2026
    		+3dSEC FORM 4

    Evidence

    27
    BL
    Burrows Scott LChief Financial Officer
    SYRESpyre Therapeutics, Inc.
    Open-market sale
    		SELL$871K
    10.0K sh
    		Jun 25, 2026Jun 26, 2026
    traded Jun 25, 2026
    		+1dSEC FORM 4

    Evidence

    12
    BL
    Burrows Scott LChief Financial Officer
    SYRESpyre Therapeutics, Inc.
    Option exercise
    		M$218K
    15.0K sh
    		Jun 25, 2026Jun 26, 2026
    traded Jun 25, 2026
    		+1dSEC FORM 4

    Evidence

    23
    BL
    Burrows Scott LChief Financial Officer
    SYRESpyre Therapeutics, Inc.
    Open-market sale
    		SELL$436K
    5,000 sh
    		Jun 25, 2026Jun 26, 2026
    traded Jun 25, 2026
    		+1dSEC FORM 4

    Evidence

    5
    BL
    Burrows Scott LChief Financial Officer
    SYRESpyre Therapeutics, Inc.
    Option exercise
    		M—
    15.0K sh
    		Jun 25, 2026Jun 26, 2026
    traded Jun 25, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MS
    Milligan SandraDirector
    SYRESpyre Therapeutics, Inc.
    Grant or award
    		A—
    8,026 sh
    		May 27, 2026May 29, 2026
    traded May 27, 2026
    		+2dSEC FORM 4

    Evidence

    20
    BL
    Burrows Scott LChief Financial Officer
    SYRESpyre Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$892K
    12.5K sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    0
    BL
    Burrows Scott LChief Financial Officer
    SYRESpyre Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    12.5K sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    24
    SS
    Sloan SheldonChief Medical Officer
    SYRESpyre Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$932K
    12.8K sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    24
    SS
    Sloan SheldonChief Medical Officer
    SYRESpyre Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$628K
    8,777 sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    27
    SS
    Sloan SheldonChief Medical Officer
    SYRESpyre Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.39M
    19.7K sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    27
    SS
    Sloan SheldonChief Medical Officer
    SYRESpyre Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.48M
    21.3K sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    8
    SS
    Sloan SheldonChief Medical Officer
    SYRESpyre Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$2.15M
    78.3K sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    7
    SS
    Sloan SheldonChief Medical Officer
    SYRESpyre Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    78.3K sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    28
    SS
    Sloan SheldonChief Medical Officer
    SYRESpyre Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$764K
    10.4K sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    28
    SS
    Sloan SheldonChief Medical Officer
    SYRESpyre Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$377K
    5,059 sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002038798-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 1, 2026
    Published
    May 1, 2026
    Ingested by INSIDER
    Nov 5, 04:01 UTC
    Last re-read
    Nov 5, 04:01 UTC

    Extracted facts

    Filer
    Sloan Sheldon
    Role
    Chief Medical Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Spyre Therapeutics, Inc.
    Ticker
    SYRE
    Shares
    400
    Price per share
    $75.37
    Value
    $30,148
    Execution date (reported)
    May 1, 2026
    Owned after transaction
    0 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 400
    • Price: $75.37

    = $30,148

    What this establishes

    Sloan Sheldon filed this Form 4 reporting a open-market sale of SYRE on May 1, 2026. It became public on May 1, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Sloan Sheldoncik:0002038798
    Issuer
    Spyre Therapeutics, Inc.cik:0001636282

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.